Exploring the role of anti-angiogenic therapies in prostate cancer： results from the phase 3 trial of sunitinib

Prostate cancer is aleading cause of cancer death in men. Despite recent advancesin our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulated...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of andrology Vol. 16; no. 4; pp. 568 - 569
Main Authors Beltran, Himisha, Kaur, Gurveen, de España, CarmenGarcías, Tagawa, ScottT
Format Journal Article
LanguageEnglish
Published China Medknow Publications & Media Pvt. Ltd 01.07.2014
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Humans
Invited Research Highlight
Male
Prednisone - therapeutic use
Prostatic Neoplasms - drug therapy
临床试验
全身治疗
前列腺癌
前列腺肿瘤
恶性肿瘤
抗血管生成
死亡原因
血管生成因子
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer is aleading cause of cancer death in men. Despite recent advancesin our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulated in prostate tumors similar to other malignancies due to imbalance of pro- and anti-angiogenic factors secreted by tumor,
Bibliography:Prostate cancer is aleading cause of cancer death in men. Despite recent advancesin our understanding and treatment of advanced disease, no systemic therapy is curative and new therapies are needed. Targeting angiogenesis is an attractive therapeutic strategy, as angiogenic pathways are upregulated in prostate tumors similar to other malignancies due to imbalance of pro- and anti-angiogenic factors secreted by tumor
31-1795/R
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1008-682X
1745-7262
DOI:10.4103/1008-682X.127822